Aarti Drugs Limited Announces Financial Results for Quarter Ended June 30, 2026
Aarti Drugs Limited has announced the audited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors considered and approved these results during a meeting held on July 31, 2026.The company maintains a single business segment in pharmaceuticals. Statutory Auditors have carried out an audit of the standalone financial results for the quarter ended June 30, 2026, expressing an unmodified audit opinion.
Standalone Financial Performance Highlights
Key operational and financial figures for Aarti Drugs Limited (Standalone) are presented below, with all amounts except for other income stated in lakhs:| Metric | Amount (in lakhs) |
|---|---|
| Revenue from Operations | 70,278 |
| Total Income (Revenue + Other Income) | 71 |
| Total Expenses | 69,324 |
| Profit before Exceptional Items and Tax | 7,036 |
| Profit attributable to the Owner of the Company | 5,013 |
The company noted that an exceptional item of Rs. 209 lakhs represented a write-off of Capital Work-in-Progress (CWIP) pertaining to the administrative building located at E1, as part of routine expansion plans.
Consolidated Results Overview
As per the consolidated financial results for the quarter ended June 30, 2026:| Metric | Amount (in lakhs) |
|---|---|
| Revenue from Operations | 2,56,531 |
| Total Income | 2,56,770 |
| Total Expenses | 235,680 |
| Profit attributable to Owner of the Company | 19,809.463 |
Corporate Structure and Auditing Details
The company operates within the pharmaceutical industry, manufacturing bulk drugs and chemicals. As on June 30, 2026, Aarti Drugs Limited has three subsidiaries: Pinnacle Life Science Private Limited, Aarti Specialty Chemicals Limited, and Pinnacle Chile SpA. The Group also includes two step-down subsidiaries, Pharma Go SpA. and Tripharma Chile SpA.The financial results were reviewed by the Audit Committee and approved by the Board of Directors on July 31, 2026. The consolidated audit included the outcomes of various entities within the group, including one subsidiary whose interim results reflected a total revenue from operations of Rs. 8,088.98 lakhs and a net profit after tax of Rs. 597.42 lakhs for the quarter ended June 30, 2026.
AARTIDRUGS Stock Price Movement
Today, Aarti Drugs Limited shares edged higher to close at ₹422.75 after gaining 2.47%. The stock traded within a daily range of ₹412 and ₹427.2, supported by a volume of 187,361 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.